Similarly, Fang et al. from the Department of Colorectal Surgery in the State Key Laboratory of Oncology in Southern China retrospectively evaluated the impact of the cell-surface receptor TROP-2 in 620 patients who had undergone surgery for colon cancer [17]. This evidence concerns the gene TACSTD2 and malignant colon neoplasm.